United States securities and exchange commission logo





                          July 7, 2022

       Sekar Kathiresan, M.D.
       Chief Executive Officer
       Verve Therapeutics, Inc.
       500 Technology Square, Suite 901
       Cambridge, Massachusetts 02139

                                                        Re: Verve Therapeutics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed July 1, 2022
                                                            File No. 333-265996

       Dear Dr. Kathiresan:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Craig Hilts